Nuformix (LON:NFX) Issues Earnings Results

Nuformix (LON:NFX – Get Free Report) issued its quarterly earnings data on Thursday. The company reported GBX (0.02) earnings per share for the quarter, Digital Look Earnings reports.

Nuformix Stock Performance

Shares of NFX opened at GBX 0.17 on Thursday. The stock has a market capitalization of £4.44 million, a P/E ratio of -4.33 and a beta of 1.55. The firm’s fifty day simple moving average is GBX 0.18 and its two-hundred day simple moving average is GBX 0.23. Nuformix has a 12 month low of GBX 0.01 and a 12 month high of GBX 0.56.

Get Nuformix alerts:

About Nuformix

(Get Free Report)

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.

Recommended Stories

• Five stocks we like better than Nuformix
• The Food Delivery War Just Entered Its Final Phase
• Bath & Body Works Stock Surged Despite Falling Sales—Here’s Why
• Dick’s Sporting Goods Isn’t Done Winning Yet
• Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak

Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.